PE20121152A1 - Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion - Google Patents

Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion

Info

Publication number
PE20121152A1
PE20121152A1 PE2012000296A PE2012000296A PE20121152A1 PE 20121152 A1 PE20121152 A1 PE 20121152A1 PE 2012000296 A PE2012000296 A PE 2012000296A PE 2012000296 A PE2012000296 A PE 2012000296A PE 20121152 A1 PE20121152 A1 PE 20121152A1
Authority
PE
Peru
Prior art keywords
amino
alkyl
pyrazoles
substitute
manufacturing
Prior art date
Application number
PE2012000296A
Other languages
English (en)
Inventor
Kristen Bjergarde
Mark Dodson
Jacques Mauger
Anil Nair
Marcel Patek
Michel Tabart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20121152A1 publication Critical patent/PE20121152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Ar-L-A ES II; X1, X2, X3 Y X4 SON CADA UNO CR'5; R'5 ES H, F; A ES FENILO, PIRIDILO SUSTITUIDO O NO CON F, Cl, SF5, ALQUILO C1-C6, ENTRE OTROS; L ES NH-CO-NH, O-CO-NH; R1 ES H; X ES O, NH; R3 ES H, ALQUILO C1-C6; R4a ES H, ALQUILO C1-C4; R4b ES H, ALQUILO C1-C4; R5 ES H, HALOGENO. SON COMPUESTOS PREFERIDOS: TRIFLUOROACETATO DE 4-[(3-{[(2-FLUOROFENIL)CARBAMOIL]AMINO}BENCIL)AMINO]-1H-PIRAZOL-3-CARBOXAMIDA; TRIFLUOROACETATO DE 4-{[3-({[2-FLUORO-3-(TRIFLUOROMETIL)FENIL]CARBAMOIL}AMINO)BENCIL]AMINO}-1H-PIRAZOL-3-CARBOXAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE KDR (RECEPTOR CON DOMINIO DE INSERCION QUINASA) Y TIE2 (TIROSINA QUINASA ESPECIFICO DE CELULAS ENDOTELIALES) UTILES EN EL TRATAMIENTO DE CANCER
PE2012000296A 2006-11-10 2007-11-09 Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion PE20121152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609812A FR2908409B1 (fr) 2006-11-10 2006-11-10 Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
PE20121152A1 true PE20121152A1 (es) 2012-09-07

Family

ID=38169388

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001548A PE20081162A1 (es) 2006-11-10 2007-11-09 Pirazoles sustituidos, composiciones que los contienen, procedimientos de fabricacion y utilizacion
PE2012000296A PE20121152A1 (es) 2006-11-10 2007-11-09 Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001548A PE20081162A1 (es) 2006-11-10 2007-11-09 Pirazoles sustituidos, composiciones que los contienen, procedimientos de fabricacion y utilizacion

Country Status (39)

Country Link
US (3) US7989439B2 (es)
EP (1) EP2091920B1 (es)
JP (1) JP5538893B2 (es)
KR (1) KR20090083456A (es)
CN (1) CN101553473B (es)
AR (1) AR063638A1 (es)
AU (1) AU2007327423B2 (es)
BR (1) BRPI0718999A2 (es)
CA (1) CA2667846A1 (es)
CL (1) CL2007003251A1 (es)
CO (1) CO6190516A2 (es)
CR (1) CR10749A (es)
CY (1) CY1116000T1 (es)
DK (1) DK2091920T3 (es)
DO (1) DOP2009000088A (es)
EA (1) EA019454B1 (es)
EC (1) ECSP099312A (es)
ES (1) ES2528385T3 (es)
FR (1) FR2908409B1 (es)
HN (1) HN2009000856A (es)
HR (1) HRP20150070T1 (es)
IL (1) IL198328A0 (es)
MA (1) MA30972B1 (es)
MX (1) MX2009004983A (es)
MY (1) MY147502A (es)
NI (1) NI200900078A (es)
NO (1) NO20091990L (es)
NZ (1) NZ576709A (es)
PE (2) PE20081162A1 (es)
PL (1) PL2091920T3 (es)
PT (1) PT2091920E (es)
SI (1) SI2091920T1 (es)
SV (1) SV2009003253A (es)
TN (1) TN2009000155A1 (es)
TW (1) TW200829556A (es)
UA (1) UA97965C2 (es)
UY (1) UY30707A1 (es)
WO (1) WO2008065282A2 (es)
ZA (1) ZA200903560B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
TWI532725B (zh) * 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
CN102432639B (zh) * 2011-09-30 2013-11-06 山东大学 1-(2-羟基-3-(苯氨基)丙基)-3-二茂铁基-1h-吡唑-5-甲酸乙酯化合物及其应用
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
CA2976766A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002088090A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
RU2005135337A (ru) * 2003-04-16 2006-06-10 Астразенека Аб (Se) Производные хиназолина для лечения злокачественного новообразования
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005012256A1 (en) * 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
EP1781653A1 (en) * 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
JP2008509982A (ja) * 2004-08-16 2008-04-03 プロシディオン・リミテッド アリール尿素誘導体
WO2006070198A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US20080161355A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HK1137988A1 (en) 2010-08-13
UY30707A1 (es) 2008-07-03
CA2667846A1 (fr) 2008-06-05
MY147502A (en) 2012-12-14
AU2007327423B2 (en) 2012-09-06
CL2007003251A1 (es) 2009-08-07
FR2908409A1 (fr) 2008-05-16
EA019454B1 (ru) 2014-03-31
JP2010509297A (ja) 2010-03-25
WO2008065282A2 (fr) 2008-06-05
AR063638A1 (es) 2009-02-04
HRP20150070T1 (hr) 2015-02-27
AU2007327423A1 (en) 2008-06-05
KR20090083456A (ko) 2009-08-03
EA200970472A1 (ru) 2009-10-30
DK2091920T3 (en) 2015-01-26
CR10749A (es) 2009-07-23
PE20081162A1 (es) 2008-10-02
WO2008065282A3 (fr) 2008-07-31
DOP2009000088A (es) 2013-06-15
PL2091920T3 (pl) 2015-04-30
SI2091920T1 (sl) 2015-02-27
JP5538893B2 (ja) 2014-07-02
US20110237801A1 (en) 2011-09-29
TW200829556A (en) 2008-07-16
US20090291984A1 (en) 2009-11-26
ECSP099312A (es) 2009-06-30
CN101553473A (zh) 2009-10-07
MA30972B1 (fr) 2009-12-01
PT2091920E (pt) 2015-02-05
EP2091920A2 (fr) 2009-08-26
SV2009003253A (es) 2009-10-27
US8420824B2 (en) 2013-04-16
FR2908409B1 (fr) 2009-01-09
US7989439B2 (en) 2011-08-02
HN2009000856A (es) 2011-10-19
US8410286B2 (en) 2013-04-02
ZA200903560B (en) 2010-08-25
ES2528385T3 (es) 2015-02-09
BRPI0718999A2 (pt) 2014-02-25
UA97965C2 (ru) 2012-04-10
MX2009004983A (es) 2009-05-22
EP2091920B1 (fr) 2014-10-22
CN101553473B (zh) 2013-06-05
NI200900078A (es) 2010-01-27
CY1116000T1 (el) 2017-01-25
TN2009000155A1 (fr) 2010-10-18
US20110237641A1 (en) 2011-09-29
CO6190516A2 (es) 2010-08-19
NO20091990L (no) 2009-06-02
IL198328A0 (en) 2010-02-17
NZ576709A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
PE20091408A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
EA201000093A1 (ru) Производные пиридазинона
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
NO20044995L (no) Heterosykliske forbindelser
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
SE0202463D0 (sv) Novel compounds
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
UY24923A1 (es) Procedimiento para preparacion de pirazoles parasiticidas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
BRPI0407841A (pt) inibidores heterocìclicos de quinase
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
WO2006047479A3 (en) C-fms kinase inhibitors

Legal Events

Date Code Title Description
FD Application declared void or lapsed